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Abstract
Background
Although prompt, effective treatment is a cornerstone of malaria control, information on pro-
vider adherence to malaria in pregnancy (MIP) treatment guidelines is limited. Incorrect or
sub-optimal treatment can adversely affect the mother and fetus. This study assessed pro-
vider knowledge of and adherence to national case management guidelines for uncompli-
cated MIP.
Methods
We conducted a cross-sectional study from September to November 2013, in 51 health
facilities (HF) and a randomly-selected sample of 39 drug outlets (DO) in the KEMRI/CDC
Health and Demographic Surveillance System area in western Kenya. Provider knowledge
of national treatment guidelines was assessed with standardized questionnaires. Correct
practice required adequate diagnosis, pregnancy assessment, and treatment with correct
drug and dosage. In HF, we conducted exit interviews in all women of childbearing age
assessed for fever. In DO, simulated clients posing as first trimester pregnant women or as
relatives of third trimester pregnant women collected standardized information.
Results
Correct MIP case management knowledge and practice were observed in 45% and 31% of
HF and 0% and 3% of DO encounters, respectively. The correct drug and dosage for
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pregnancy trimester was prescribed in 62% of HF and 42% of DO encounters; correct pre-
scription occurred less often in first than in second/ third trimesters (HF: 24% vs. 65%,
p<0.01; DO: 0% vs. 40%, p<0.01). Sulfadoxine-pyrimethamine, which is not recommended
for malaria treatment, was prescribed in 3% of HF and 18% of DO encounters. Exposure to
artemether-lumefantrine in first trimester, which is contraindicated, occurred in 29% and
49% of HF and DO encounters, respectively.
Conclusion
This study highlights knowledge inadequacies and incorrect prescribing practices in the
treatment of MIP. Particularly concerning is the prescription of contraindicated medications
in the first trimester. These issues should be addressed through comprehensive trainings
and increased supportive supervision. Additional innovative means to improve care should
be explored.
Introduction
Approximately 125 million pregnancies occur in areas at risk of Plasmodium falciparum and P.
vivax infections every year; an estimated 1.3 million of these occur in Kenya [1]. Malaria in preg-
nancy (MiP) can have devastating consequences for the woman and her unborn baby, including
maternal anemia, fetal loss, intrauterine growth retardation, premature delivery and low birth
weight (LBW) with increased risk for neonatal death [2]. In line with World Health Organiza-
tion (WHO) recommendations, the Kenya Ministry of Health (MoH) recommends that preg-
nant women use long-lasting insecticidal nets (LLINs), intermittent preventive treatment in
pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP), and receive prompt and effective diag-
nosis and treatment of malaria with a safe drug in order to prevent adverse consequences.
The Kenya National Treatment Guidelines recommend artemether-lumefantrine (AL), an
artemisinin combination therapy (ACT), as the first-line treatment for uncomplicated P. falcip-
arummalaria in the general population and women in second and third trimesters of preg-
nancy. However, due to insufficient safety data on ACTs [3–5], AL is contraindicated in first
trimester, and oral quinine is recommended instead [6–8]. In practice, all women of child-bear-
ing age (WOCBA) must be assessed for pregnancy and gestational age. Since 2010, Kenya Min-
istry of Health (MoH) treatment guidelines recommend universal parasitological diagnosis.
Antimalarial treatment on the basis of clinical suspicion of malaria should only be considered
in situations where a parasitological diagnosis is not accessible, particularly in vulnerable popu-
lations such as pregnant women [6]. We found that 77% of WOCBA and pregnant women in
health facilities (HFs) and 5% in drug outlets (DOs) in Kenya received parasitologically con-
firmed diagnosis [9].
Limited data exists on healthcare provider adherence to case management guidelines for
MiP. Recent studies from Kenya have reported high levels (80–90%) of adherence to malaria
treatment guidelines for the general population [10–12]. However, a recent systematic review
and meta-analysis of global MiP case management reported that overall, healthcare providers
followed the pregnancy specific treatment guidelines for malaria in 28% of first trimester
encounters and 72% of second and third trimester encounters [13]. Inadvertent exposure to
ACTs in the first trimester and continued use of ineffective treatment regimens, such as SP, has
been observed in a number of countries; very few providers know that ACTs are potentially
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teratogenic (harmful to foetal development) [13–18]. In Uganda, 70% of women with a first-
trimester pregnancy received a contraindicated antimalarial and less than 6% received quinine,
the drug recommended for treatment of malaria in the first trimester of pregnancy [18]. In
Tanzania, 43% of drug dispensers in registered pharmacies offered AL regardless of the preg-
nant client’s gestational age; only 20% knew that AL was contraindicated during the first tri-
mester [15].
Understanding provider prescribing behaviour in pregnant women is essential to ensure ade-
quate case management and to minimize potential harmful exposures; this is relevant in health
facilities and drug outlets because each comprise a significant proportion of healthcare service
utilization [19]. About 25% of the total population are WOCBA and up to 14% could be preg-
nant at any time; therefore, it is crucial that providers recognize potentially teratogenic medica-
tions and assess WOCBA for pregnancy status and gestational age. This cross-sectional study
assessed healthcare provider and drug dispenser prescribing behaviors and knowledge of
malaria treatment guidelines for pregnant clients in a malaria-endemic region of western Kenya.
Methods
Knowledge of MiP guidelines and self-reported prescribing behavior for MiP case management
was assessed by structured provider questionnaires administered to healthcare providers and
drug dispensers. Adherence to the National Malaria Treatment Guidelines (assessed via pre-
scribing practice) was observed by a) exit interviews with WOCBA (18–49 years) and pregnant
clients being treated for febrile illness at all HFs within the study area, and b) use of a simu-
lated-client approach within randomly sampled DOs. Provider knowledge questionnaires were
administered following completion of the provider practice component to avoid influencing
provider behavior.
Study Site & Sampling
The study was conducted from September to November 2013, in rural Siaya County in western
Kenya. The study area included the Kenya Medical Research Institute (KEMRI) and U.S. Cen-
ters for Disease Control and Prevention (CDC) Public Health Collaboration Health and Demo-
graphic Surveillance System (HDSS)[20] as well as a 5 km radius surrounding the HDSS.
Malaria transmission is perennial and holo-endemic. In this area, approximately 20% of preg-
nant women are parasitemic at first antenatal clinic visit [21], and 18% of women delivering in
Siaya District Hospital had placental malaria [22].
Health facility selection. All HFs in the HDSS area and within a 5km radius surrounding
the HDSS area were assessed for eligibility. Facilities were eligible if they provided outpatient
care and the facility in-charge consented to participate. Facilities with ongoing studies that
could have influenced the study results were excluded.
Drug outlets selection. Prior to the start of data collection, a census was conducted of all
registered and unregistered (i.e., informal) DOs selling antimalarial drugs within the HDSS
border [23]. DOs were eligible if they sold antimalarials and consented to participate. All
home-based shops were excluded given that provider practice was assessed via simulated client
which was not feasible in this setting. This sample size allowed estimation of the proportion of
providers (one per facility) with adequate knowledge with 14% precision at 80% power, assum-
ing that 45% of providers have adequate knowledge and prescribing practice [15].
Data Collection
Provider surveys in health facilities & drug outlets. A fieldworker administered the
structured knowledge questionnaire to one to two providers per HF (dependent upon number
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of staff treating WOCBA and pregnant women) and one provider per DO to assess knowledge
and self-reported prescribing practice. Providers were selected from all providers who treated
WOCBA for malaria and were available at the time of interview. These interviews were carried
out immediately following the completion of exit interviews and one week after client simula-
tions (described below) by a different fieldworker.
Exit interviews in health facilities. All women who completed a provider consultation in
either the outpatient department (OPD) or antenatal care (ANC) clinic were approached after
receiving all prescribed medications by fieldworkers trained for 10 days on proper interviewing
techniques. Fieldworkers assessed eligibility and obtained informed consent from women pre-
senting with febrile illness. Facilities were visited for a minimum of one day and a maximum of
10 days. Field workers remained at a facility for consecutive days either until they had inter-
viewed at least one woman in each of the following categories per facility: 1) WOCBA who could
potentially be pregnant, 2) early pregnancy (first trimester, defined as up to 14 weeks inclusive),
and 3) late pregnancy (second and third trimesters, defined as 15 weeks or greater), or after 10
consecutive clinic days. Exit interviews were conducted following a structured questionnaire.
Pregnancy status was based on patient report; gestational age and trimester were calculated from
date of last menstrual period (LMP). In encounters where an antimalarial contraindicated in
pregnancy had been prescribed, the patient was given the recommended treatment by the study
clinician and instructed not to take the incorrect medication. Fieldworkers were positioned out-
side of the clinic and the interactions could not be overheard or observed by clinic staff; health
providers were not aware of changes to medications until after completion of the study.
Simulated clients in drug outlets. The simulated-client (i.e., mystery clients [24,25])
approach was used to assess prescribing practice within DOs. Three scenarios (WOCBA, early
pregnancy, late pregnancy) were simulated at each outlet. Female fieldworkers presented as
either WOCBA or in early pregnancy, and male fieldworkers presented as the husband of a
WOCBA or woman in third-trimester pregnancy. A single provider-client simulation had the
potential to include up to two scenarios: non-pregnant and pregnant. The simulated clients
were trained not to disclose pregnancy status unless it was asked by the dispenser. If dispensers
failed to assess pregnancy status, the simulated clients would disclose pregnancy status after
being advised on a treatment regimen; this pregnancy scenario was then assessed based on
changes in practice, or lack thereof, made after pregnancy disclosure. The checklist for the sim-
ulated-client encounter was completed immediately after each interaction.
Definitions
Correct practice and adequate knowledge definitions (Table 1) were based on the 2010 Kenya
National Malaria Treatment Guidelines (MTGs) [7] and the 2010 WHOMalaria Treatment
Guidelines [6]. Correct case management required adequate diagnosis (additional information
presented in [9]), pregnancy assessment, and treatment with correct drug and dosage. For the
knowledge assessment, providers were asked to name the recommended first line therapy,
while for exit interviews and client simulations (practice component), either first- or second-
line medications were considered correct.
Data Management & Statistical Analysis
Data from the provider surveys were collected via personal digital assistant (PDA), and data
from simulated clients and exit interviews were collected via scannable forms. We used SAS 9.3
(SAS Institute, Cary, NC, USA) for analysis.
Chi-square test or Fisher exact test were used to assess statistical significance (p0.05) of
comparisons between categorical variables. We calculated the proportion of providers,
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accounting for clustering at the facility level, who adequately assessed for pregnancy and
correctly prescribed treatment (correct treatment was defined as prescribing the correct med-
ication and dosage); these measures were used to define overall correct MiP case manage-
ment practice. Logistic regressions were performed at the individual-provider level,
accounting for clustering at the facility level to identify significant (p0.05) predictors of
case management knowledge. Intra-cluster correlation at the facility level was accounted for
in all analysis.
Ethics
The study was approved by the Kenya Medical Research Institute (KEMRI) Ethical Review
Committee and the institutional review boards of the Centers for Disease Control and Preven-
tion, Liverpool School of Tropical Medicine, and Emory University. Written informed consent
was obtained from all providers and patients prior to interviews. the component of the study
assessing prescribing behaviour from drug outlets which involved simulated clients, verbal con-
sent was sought from all drug outlet dispensers during the drug-outlet mapping for future par-
ticipation in a study for assessment MiP treatment using simulated clients. It was not possible
to obtain informed consent at the time of the simulated client interaction, as it was critical to
the study design that the provider was unaware that the client was assessing practice. No per-
sonal information on the drug dispenser was collected during the simulated client interview,
thus verbal consent (documented in the drug-outlet mapping case report forms) was consid-
ered sufficient and was approved by all ethical review boards.
Table 1. Definitions of Correct Practice & Adequate Knowledge.
Correct Malaria Diagnosis
Utilization of microscopy or rapid diagnostic test
Clinical diagnosis when diagnostic test unavailable
Correct Pregnancy Assessment
Inquired about pregnancy and/ or offered pregnancy test
Inquired about LMP, gestational age, or measured fundal height or palpated
Correct Treatment & Dosage
Acceptable Knowledge Answers Acceptable Prescriptions in Practice
Non-pregnant Non-pregnant
1st-line: Artemether-lumefantrine Artemether-lumefantrine
2nd-line: DHA-piperaquine DHA-piperaquine
Quinine
1st Trimester 1st Trimester
Quinine Quinine
2nd/3rd Trimester 2nd/3rd Trimester
Quinine Quinine
Artemether-lumefantrine Artemether-lumefantrine
DHA-piperaquine
Treatment regimens:
Artemether-lumefantrine tablets (20/120 mg): 4 tablets, 2 times daily for 3 days (4x2x3)
DHA-piperaquine tablets (40/320 mg): 3 or 4 tablets, once daily for 3 days (3x1x3) or (4x1x3)
Quinine: 2 tablets of 300 mg, 3 times daily for 7 days (2x3x7)*
Acronyms: LMP, date of last menstruation period; DHA, dihydroartemisinin,
*Differs from standard adult dosing regimen of 5 full days
doi:10.1371/journal.pone.0145616.t001
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Results
Provider Knowledge of National Malaria Treatment Guidelines
We surveyed 112 providers across 86 facilities; 75 in HFs and 37 in DOs. Of respondents, 44%
were nursing staff, 16% were clinical officers or physicians, 18% pharmacists, and 13% were
shopkeepers. Sixty-nine percent of providers stated that they both prescribed and dispensed
medication (Table 2).
Overall, 75% (84/112) of providers were aware of the National Malaria Treatment Guide-
lines (MTGs); knowledge was higher among HF than DO providers (S1 Table). Eighty-eight
percent (99/112) of providers reported ‘always’ or ‘sometimes’ performing a pregnancy assess-
ment; 79% (78/99) of whom reported asking for LMP, and 48% reported offering a pregnancy
test (48/99).
Forty-seven percent (35/75) of HF providers knew the correct first-line treatment and dos-
age for all pregnancy scenarios compared to none (0%) of the 37 drug dispensers. Over half
(56%) of HF providers and no drug dispensers knew the correct treatment for first trimester
patients (p<0.01); 85% (64/75) of HF and 41% (15/37) of drug outlet providers knew the cor-
rect treatment for second and third trimester patients (p<0.01). Provider knowledge was con-
siderably higher for first-line treatment versus second-line treatment (82% v 16%, p<0.01)
(Table 3).
SP was incorrectly cited as the appropriate treatment for acute malaria in the following sce-
narios: a) first- and/or second-line treatment for adults by 3% of HF and 10% of DO providers,
b) in first trimester pregnant patients by 9% and 39% of providers, c) in second and third
Table 2. Provider characteristics from the provider survey on national malaria treatment guidelines.
Overall Health facilities Drug Outlets
Provider/Dispenser Characteristics N % N % N %
112 75 37
Sex
Male 54 48.2 39 52.0 15 40.5
Female 58 51.8 36 48.0 22 59.5
Respondent Cadre
Registered Nurse 33 29.5 32 42.7 1 2.7
Enrolled Nurse 16 14.3 16 21.3 0 0.0
Clinical Ofﬁcer/Physician 18 16.1 17 22.7 1 2.7
Pharmacist 20 17.9 5 6.7 15 40.5
Shopkeeper 15 13.4 0 0.0 15 40.5
CHW/VR/other* 10 8.9 5 6.7 5 13.5
Professional Qualiﬁcation
Primary School 9 8.0 2 2.7 7 18.9
Secondary School 23 20.5 7 9.3 16 43.2
Higher Education 19 17.0 13 17.3 6 16.2
Clinical Ofﬁcer/MD 14 12.5 13 17.3 1 2.7
Registered Midwife/Nurse 22 19.6 20 26.7 2 5.4
Enrolled Midwife/Nurse 11 9.8 10 13.3 1 2.7
Pharmacist 4 3.6 1 1.3 3 8.1
Other technical 10 8.9 9 12.0 1 2.7
* CHW—community health worker, VR = village reporter, ‘other’ included clerk, economist, statistical clerk, and support staff
doi:10.1371/journal.pone.0145616.t002
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trimester by 1% and 18% of providers, and d) for treatment of severe malaria in pregnancy by
3% and 10% of providers respectively. Two-thirds cited IPTp with SP as a preventive measure
for MiP; however, only 67% of HF and 32% of DO providers knew that SP could be used only
as preventive therapy and not as treatment. Additionally, 4% of HF and 10% of DO providers
thought AL could be used as preventive therapy and another 41% of DO providers were unable
to cite a drug for preventive treatment. An ACT was incorrectly cited as the appropriate treat-
ment in first-trimester pregnancies by 5% of HF providers and 18% of drug-outlet providers;
56% of providers (71% and 27%, respectively) were aware that ACTs are contraindicated in
first trimester (S2 Table).
Predictors of MiP case management knowledge. Significant predictors of adequate
knowledge of MiP case management in the adjusted model included facility type and malaria
case management training (Table 4). HF providers were more likely to possess adequate knowl-
edge of correct case management than their DO counterparts (adjusted OR (aOR) = 2.8; 95%
CI [0.9–8.4]) although this was not statistically significant. Having attended malaria case man-
agement training increased the likelihood of having adequate knowledge (aOR = 3.6; 95% CI
[1.3–9.7]). Other factors including age, gender, respondent cadre, and education were also ana-
lysed but were not significantly associated with provider knowledge.
MiP Case Management Practice: Exit Interviews in Health Facilities
After excluding 9 HFs due to ongoing studies that could have influenced study results, 52 HFs
were eligible for the study; supervisors in 51 facilities (including four hospitals, 19 health cen-
ters, and 28 dispensaries) consented to participate (S3 Table). A total of 208 eligible patients
were interviewed across participating HFs: 111 non-pregnant women, 21 women in the first
trimester of pregnancy, and 76 women in the second and third trimesters (S4 Table).
Pregnancy assessment. Only 51% (107/208) of all patients were assessed for pregnancy
status; 63% (61/97) of pregnant women were asked for their LMP (Table 5). A pregnancy test
was offered to only 9% (19/208) women; offering a pregnancy test was significantly associated
with first trimester of pregnancy, as might be expected, given that later in pregnancy, the status
becomes more obvious on examination. Study fieldworkers identified 23 women who reported
Table 3. Adequate Provider Knowledge of Malaria in Pregnancy based on National malaria treatment guidelines comparing health facilities to
drug outlets.
Overall Health Facilities Drug Outlets P-value*
n = 112 % 95% CI n = 75 % 95% CI n = 37 % 95% CI
Consequences of MiP 110 98.2 (95.7, 100.0) 74 98.7 (96.0, 100.0) 36 97.3 (92.0, 100.0) 0.61
Awareness of MTGs 84 75.0 (66.1, 83.9) 74 98.7 (96.0, 100.0) 10 27.0 (12.4, 41.6) <0.01
Pregnancy Assessment 88 78.6 (70.7, 86.4) 70 93.3 (87.9, 98.8) 18 48.6 (32.2, 65.1) <0.01
Treatment & Dosage 35 31.3 (22.0, 40.5) 35 46.7 (34.4, 59.0) 0 0.0 <0.01
NP-1st Line 92 82.1 (74.9, 89.4) 69 92.0 (86.1, 97.9) 23 62.2 (46.2, 78.1) <0.01
NP-2nd Line 18 16.1 (8.9, 23.2) 15 20.0 (10.6, 29.4) 3 8.1 (0.0, 17.1) <0.01
1st Tri- 1st Line 42 37.5 (27.6, 47.4) 42 56.0 (43.6, 68.4) 0 0.0 <0.01
2nd/3rd Tri- 1st Line 79 70.5 (61.7, 79.3) 64 85.3 (77.1, 93.6) 15 40.5 (24.4, 56.7) <0.01
Severe MiP 69 61.6 (52.1, 71.1) 61 81.3 (71.8, 90.9) 8 21.6 (8.1, 35.2) <0.01
Adequate Knowledge 34 30.4 (21.3, 39.4) 34 45.3 (33.2, 57.5) 0 0.0 <0.01
*Fisher Exact used for strata with <5 observations
Acronyms: MTG, malaria treatment guidelines, MiP, malaria in pregnancy, NP, non-pregnant; Tri, trimester of pregnancy
doi:10.1371/journal.pone.0145616.t003
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an LMP of greater than six weeks; none of whom were assessed for pregnancy status by the
provider.
Treatment prescribed. An antimalarial medication was prescribed to 98% (204/208) of
women; the most frequent antimalarials prescribed were AL (83%), followed by quinine (14%),
then SP (3%). Sixty-two percent (129/208) of women received the correct treatment (Table 6).
Despite being contraindicated in first trimester, AL was prescribed in first trimester to six of 21
(29%) women. While the majority (73%, 125/172) of prescriptions for AL were for the correct
dosage, the correct dose of quinine was prescribed only 29% (8/28) of the time. In all 20 incor-
rect-quinine-dosage encounters, this resulted in sub-therapeutic dosing, and in 70% (14/20) of
these encounters, patients were prescribed less than the standard 5-day adult course of quinine.
Due to the fact that AL was frequently prescribed irrespective of trimester, the correct drug and
dosage was prescribed more frequently to non-pregnant patients (68%) and those in the second
and third trimester of pregnancy (63%) than to those in first trimester (24%, p = 0.001).
Table 4. Provider Characteristic Predictors of Adequate Knowledge of Malaria in Pregnancy Case-Management.
Provider Characteristic N % Crude OR 95% CI P Adjusted OR* 95% CI P
Facility Type** 112
Health Facilities 75 67.0 4.3 (1.6, 11.7) <0.01 2.8 (0.9, 8.4) 0.07
Drug Outlets (reference) 37 33.0 — — — — — —
Malaria Management Training
None 51 45.5 — — — — — —
Yes 61 54.5 4.8 (1.9, 12.1) <0.01 3.6 (1.3, 9.7) 0.01
Sources of Information (reference = 'No')
CME as a source of info 63 56.3 1.5 (1.8, 10.4) <0.01 — — —
Knowledge Variable (reference = 'Not Known')
1st Trimester as Contraindication 63 56.3 6.1 (2.1, 17.8) <0.01 — — —
Return to Facility if no Improvement 58 51.8 2.7 (1.2, 5.9) 0.02 — — —
Sleep under ITN 103 92.0 3.7 (0.9, 14.8) 0.07 — — —
SP can only be used for MiP Prevention 62 55.4 2.6 (1.0, 6.5) 0.05 — — —
*Adjusted model included facility type and malaria diagnostic training. CME & Knowledge variables could not be included in the multivariate model as the
model did not converge when they were included.
**Facility type is stratiﬁed at the health facility versus drug outlet level; the fully stratiﬁed model was unstable due to quasi-complete separation of data
points.
doi:10.1371/journal.pone.0145616.t004
Table 5. Pregnancy assessment practice in health facilities as observed through exit interviews stratified across pregnancy status.
Overall Non-Pregnant 1st Trimester 2nd/3rd Trimester
N % 95% CI N % 95% CI N % 95% CI N % 95% CI P-value
All Patients 208 111 21 76
Pregnancy Status Inquiry 91 43.8 (35.3, 52.2) 29 26.1 (16.9, 35.4) 16 76.2 (55.2, 97.2) 46 60.5 (49.2, 71.8) <0.01
Pregnancy Test Offered 19 9.1 (5.1, 13.1) 4 3.6 (0.3, 6.9) 8 38.1 (16.4, 59.8) 7 9.2 (2.3, 16.1) <0.01
LMP Inquiry 88 42.3 (33.4, 51.4) 27 24.3 (14.6, 34.0) 15 71.4 (49.7, 93.2) 46 60.5 (49.9, 71.2) <0.01
Pregnancy Duration/Timing 66 68.0 (56.5, 79.6) NA 13 61.9 (38.0, 85.8) 53 69.7 (58.1, 81.4) 0.5
Additional Conﬁrmation* 41 42.3 (30.9, 53.6) NA 5 23.8 (4.0, 43.6) 36 47.4 (35.2, 59.6) 0.06
Correct pregnancy assessment 107 51.4 (41.9, 61.0) 27 24.3 (14.6, 34.0) 17 81.0 (60.9, 100.0) 63 82.9 (75.0, 90.8) <0.01
* Additional conﬁrmation included palpation in ﬁrst trimester, and palpation or observation in second/third trimester encounters.
doi:10.1371/journal.pone.0145616.t005
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Table 6. Malaria treatment practice in health facilities as observed through exit interviews stratified across pregnancy status.
Overall Non-Pregnant 1st Trimester 2nd/3rd Trimester
N % 95% CI N % 95% CI N % 95% CI N % 95% CI P-
value
208 111 21 76
Prescribed Antimalarials 204 98.1 110 99.1 20 95.5 74 97.4
Proper Dosage (tabs x doses x
days)*
0.00 0.0
Artemether-lumefantrine 172 82.7 (77.5,
87.9)
105 94.6 (90.2,
98.9)
6 28.6 (4.0, 53.2) 61 80.3 (70.8,
89.8)
<0.01
(4x2x3) 125 72.7 (61.8,
82.6)
74 70.5 (55.4,
85.6)
5 83.3 (59.6,
100.0)
46 75.4 (58.4,
92.4)
<0.01
DHA-Piperaquine 2 1.0 (0.0, 2.3) 2 1.8 (0.0, 4.5) 0 0.0 0 0.0
(3x1x3) 1 50.0 (0.0, 1.5) 1 50.0 (0.0, 2.8) 0.0 0.0
Quinine 28 13.5 (9.1,
17.8)
4 3.6 (0.0, 8.1) 12 57.1 (33.6,
80.7)
12 15.8 (7.0, 24.6) <0.01
(2x3x7) 7 25.0 (9.2,
40.8)
0 0.0 5 41.7 (11.6,
71.7)
2 16.7 (0.0, 39.8) <0.01
(150mgxN) 1 3.6 (0.0,
11.0)
1 25.0 (0.0,
74.4)
0 0.0 0 0.0
Sulfadoxine Pyrimethamine 7 3.4 (0.4, 6.4) 1 0.9 (0.0, 2.8) 2 9.5 (0.0, 22.0) 4 5.3 (0.0, 11.3) 0.06
(3x1x1) 5 71.4 (46.8,
96.0)
0 0.0 2 100.0 (0.0,
100.0)
3 75.0 (50.0,
100.0)
0.42
Artemether Injection 1 0.5 (0.0, 1.5) 1 0.9 (0.0, 2.8) 0 0.0 0 0.0
(60mg) 1 100.0 (0.0,
100.0)
1 100.0 (0.0,
100.0)
0.0 0.0
Correct Drug 194 93.3 111 100.0 12 57.1 74 97.4
Correct Drug & Dosage 129 62.0 (52.2,
71.8)
76 68.5 (57.2,
79.7)
5 23.8 (5.3, 42.3) 48 63.2 (49.6,
76.7)
<0.01
Concomitant Medications 0.0
Analgesic 147 70.7 (61.2,
80.2)
79 71.2 (59.3,
83.0)
16 76.2 (57.7,
94.7)
52 68.4 (55.7,
81.1)
0.78
Antibiotic 74 35.6 (26.5,
44.7)
37 33.3 (21.9,
44.8)
6 28.6 (10.2,
47.0)
31 40.8 (28.9,
52.6)
0.4
1st Antimalarial dose Directly
Observed
50 24.0 (14.4,
33.4)
25 22.5 (10.2,
34.8)
4 19.0 (2.9, 33.5) 21 27.6 (15.4,
39.9)
0.59
Treatment Advice 0.0
Reason for Prescription 58 27.9 (20.7,
36.1)
32 28.8 (20.9,
38.3)
5 23.8 (5.3, 44.3) 21 27.6 (16.6,
38.7)
0.88
Side Effects 14 6.7 (3.1,
10.8)
5 4.5 (0.5, 8.8) 4 19.0 (1.2, 40.8) 5 6.6 (1.2, 12.3) 0.03
Any other advice** 45 21.6 (15.0,
28.3)
21 18.9 (11.0,
26.8)
5 23.8 (2.8, 44.8) 19 25.0 (14.0,
36.0)
0.63
Any treatment Advice 82 39.4 (31.2,
47.6)
42 37.8 (27.5,
48.2)
10 47.6 (24.5,
70.8)
30 39.5 (27.0,
52.0)
0.72
*The denominator for percentage for correct dosage is based on the number of patients receiving the speciﬁc antimalarial.
**Any other advice includes patient-reported advice by the provider including emphasis of complete medication regimen, eating prior to taking medication,
sleeping under ITNs, etc.
doi:10.1371/journal.pone.0145616.t006
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Correct case management was observed in only 31% (65/208) of patients, with no significant
difference across HF types (S5 Table).
MiP Case Management Practice: Simulated Clients in Drug Outlets
Twenty-seven home-based shops were excluded from the sampling frame, resulting in 152 con-
senting DOs. Thirty-nine DOs were then randomly selected (S3 Table). Seventy-seven simu-
lated client-provider encounters with a total of 147 scenarios were completed at 39 DOs
(Fig 1). Between 37 and 72 simulations per pregnancy scenario were completed (S3 Table).
Pregnancy assessment. DO providers inquired about pregnancy in only 4 of 77 (5%)
encounters; pregnancy tests were never offered. DO providers were informed of positive preg-
nancy status in 70 encounters when there was no initial inquiry on the part of the provider.
Pregnancy trimester was assessed in 57% (40/70) of encounters. Inquiry about pregnancy ges-
tation was 77% (27/35) in registered pharmacies and 73% (40/55) in informal drug shops with
general shops significantly lower at 31% (20/64), (p<0.01); this did not differ between encoun-
ters where the client was the patient versus the patient’s relative (Table 7).
Treatment dispensed. Antimalarials for treatment of malaria were dispensed in 83%
(122/147) of all DO encounters; most commonly AL (76%), followed by SP (21%). Quinine
was never dispensed (Table 8). There were significant differences in correct treatment across
pregnancy status, with 71% (46/72) of non-pregnant, 54% (15/38) of third-trimester, and 0%
(0/37) of first-trimester client simulations receiving appropriate treatment (p<0.01). The DO
providers were 7.0 times more likely to prescribe SP for treatment of acute malaria to pregnant
Fig 1. Drug Outlet & Simulation Algorithm.
doi:10.1371/journal.pone.0145616.g001
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versus non-pregnant women (95% CI, [2.4–24.9]), p<0.0001). Among providers that were
aware the client was in the first trimester, over half (62%) prescribed AL; all but one of the
remaining clients were prescribed SP (34%). Artemether-lumefantrine was initially prescribed
to over 90% (111/122) of simulated client patients; in 23% (16/70) of encounters in which the
provider was informed that the patient was pregnant treatment was changed from AL to SP
regardless of trimester, and in another 16% (11/70), AL was withdrawn and the patient was
referred to a health facility. Correct case management was observed in only 3% (4/147) of sim-
ulations, with no significant difference across outlet types (S7 Table).
Discussion
This study found that in Siaya County, Kenya, provider knowledge of the treatment for case
management of MiP in both health facilities and drug outlets was poor, with resultant poor lev-
els of observed correct MiP case management practice, particularly in the first trimester of
pregnancy (10%). Providers consistently failed to assess for pregnancy, despite the demon-
strated knowledge that this step was necessary; practice was considerably worse in DOs than
HFs. Although women in second- and third-trimester of pregnancy generally received appro-
priate therapy, less than one-third of women in first trimester were treated appropriately. Of
particular concern, incorrect prescribing practices included provision of AL in early pregnancy,
suboptimal dosing of quinine, and use of SP for treatment. These observations highlight the
urgent need to monitor and ensure delivery of quality MIP case management.
Pregnancy Assessment
Pregnancy assessment was very poor. Although 79% of providers reported assessing for preg-
nancy on the knowledge assessment, less than half of the women in HFs and none of the female
Table 7. Pregnancy assessment practice in drug outlets as observed through simulated clients across pregnancy status.
Overall WOCBA/1st Trimester Husband of WOCBA/3rd
Trimester
N % 95% CI N % 95% CI N % 95% CI P-value
Pregnancy Inquiry 77 38 39
Unprompted Pregnancy Inquiry 4 5.2 (3.7, 11.1) 0 0.0 4 10.3 (3.5, 24.2) 0.29
Conﬁrmation
Timing 2 50.0 (0.0, 100.0) 0 0.0 2 50.0 (0.0, 100.0)
LMP 0 0.0 0 0.0 0 0.0
Gestation 2 50.0 (0.0, 100.0) 0 0.0 2 100.0
Pregnancy Test Offered 0 0.0 0 0.0 0 0.0
None 2 50.0 (0.0, 100.0) 0 0.0 2 50.0 (0.0, 100.0)
Informed Provider of Pregnancy Status 70 36 34 0.72
Conﬁrmation
Timing 40 57.1 (45.6, 69.4) 21 58.3 (41.4, 75.2) 19 55.9 (39.0, 72.2) 1.00
LMP 2 5.0 (0.0, 11.5) 2 5.6 (0.0, 22.9) 0 0.0
Gestation 38 95.0 (88.5, 100.0) 19 52.8 (77.1, 100.0) 19 100.0
Pregnancy Test Offered 0 0.0 0 0.0 0 0.0
None 30 42.9 (30.6, 54.4) 15 41.7 (24.0, 57.1) 15 44.1 (61.0, 27.8) 1.00
Correct Pregnancy Assessment* 48 62.3 (53.1, 65.5) 23 57.5 (48.8, 66.3) 25 61.0 (51.6, 69.4) 0.93
*Correct Pregnancy Assessment indicates that the provider conﬁrmed pregnancy status via LMP, gestational inquiry, or pregnancy test
doi:10.1371/journal.pone.0145616.t007
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simulated clients in DOs were assessed for pregnancy in practice, indicating that providers
know they should assess WOCBA for pregnancy but consistently fail to do so. While 52% of
HF providers assessed for gestational age, DO providers almost never did so, even when made
aware that the woman was pregnant. The failure of providers to assess for pregnancy in a large
proportion of women is problematic and may result in inadvertent exposure to potential
teratogens, such as ACTs, in early pregnancy. These encounters also represent missed opportu-
nities to refer women to ANC or to remind women of the benefits of early antenatal care in an
area where most women initiate ANC late in pregnancy [26].
Table 8. Correct Treatment and Dosage Characteristics by Pregnancy Status in Drug Outlets.
Overall WOCBA 1st Trimester 2nd/3rd Trimester
N % 95% CI N % 95% CI N % 95% CI N % 95% CI P-
value
147 72 37 38
Prescribed Antimalarials 122 83.0 65 90.3 29 78.4 28 73.7
Correct Dosage (tabs x doses x
days)*
Artemether-lumefantrine 93 76.2 (66.3,
86.2)
59 90.8 (81.3,
100.0)
18 62.1 (43.5,
80.6)
16 57.1 (37.9, 76.4) <0.01
(4x2x3) 75 61.5 (51.1,
71.9)
46 70.8 (59.5, 82.0) 14 48.3 (29.1,
67.4)
15 53.6 (34.1, 73.0) 0.04
Artesunate amodiaquine 1 0.8 (0.0, 2.5) 1 1.5 (0.0, 4.7) 0 0.0 0 0.0
(4x1x3) 0 0.0 0 0.0 0 0.0 0.0
Amodiaquine 2 1.6 (0.0, 5.0) 1 1.5 (0.0, 4.7) 1 3.4 (0.0, 10.4) 0 0.0
(3x1x1) 2 1.6 (0.0, 5.0) 1 1.5 1 3.4 (0.0, 10.4) 0.0
Quinine 0 0.0 0 0.0 0 0.0 0 0.0
(2x3x7) 0 0.0 0.0 0.0 0.0
Sulfadoxine Pyrimethamine 26 21.3 (13.1,
29.5)
4 6.2 (0.0, 13.6) 10 34.5 (16.3,
52.7)
12 42.9 (23.6, 62.1) <0.01
(3x1x1) 20 16.4 (8.8, 24.0) 4 6.2 (0.0, 13.6) 6 20.7 (5.2, 36.2) 10 35.7 (17.0, 54.4) <0.01
Correct Drug 77 63.1 61 93.8 0 0.0 16 57.1
Correct Drug & Dosage 61 50.0 (42.5,
57.5)
46 70.8 (59.5, 82.0) 0 0.0 15 53.6 (34.1, 73.0)
Concomitant Medications
Analgesic 90 73.8 (61.2,
86.4)
47 72.3 (59.5, 85.1) 24 82.8 (68.3,
97.2)
19 67.9 (49.7, 86.1) 0.14
Multivitamin 2 1.6 (0.0, 4.8) 0 0.0 0 0.0 2 7.1 (0.0, 17.2)
Treatment Advice
Dosage directions 106 86.9 (79.2,
94.6)
55 84.6 (68.3, 97.2) 24 82.8 (68.3,
97.2)
27 96.4 (89.2,
100.0)
0.12
Visual Instructions 69 56.6 (43.9,
69.2)
34 52.3 (38.4, 66.2) 18 62.1 (43.5,
80.6)
17 60.7 (41.7, 79.7) 0.47
Emphasize need to ﬁnish dose 8 6.6 (0.0, 13.4) 3 4.6 (0.0, 9.9) 1 3.4 (0.0, 10.4) 4 14.3 (0.7, 27.9) 0.01
Side effects 2 1.6 (0.0, 4.0) 1 1.5 (0.0, 4.7) 0 0.0 1 3.6 (0.0, 10.8)
Advice if symptoms persist 5 4.1 (0.0, 9.0) 3 4.6 (0.0, 9.9) 2 6.9 (0.0, 16.6) 0 0.0
Any treatment advice 106 86.9 (79.2,
94.6)
55 84.6 (76.2, 93.1) 24 82.8 (68.3,
97.2)
27 96.4 (89.2,
100.0)
0.12
*Percentage for correct dosage is based on the numbers receiving the speciﬁc antimalarial
doi:10.1371/journal.pone.0145616.t008
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Treatment Prescribed
Women in the first trimester were significantly less likely to receive the correct treatment than
women in later pregnancy or non-pregnant women. Overall, contraindicated regimens were
prescribed in 65% of first-trimester women, consistent with previous observations in this area
and neighbouring Uganda [18,27]. This may reflect a reluctance to ask about the culturally sen-
sitive issue of early pregnancy, or a lack of knowledge by healthcare providers regarding poten-
tial teratogenicity, as only 56% of providers reported that ACTs were contraindicated in the
first trimester. Regardless, provider training should emphasize the potential teratogenicity of
ACTs and other potentially harmful drugs, and highlight the importance of identifying preg-
nant women as early as possible. Five of the providers who were aware that ACTs are contrain-
dicated in the first trimester incorrectly cited SP as the recommended treatment. There was a
tendency among DO providers to withdraw AL and refer the woman to a health facility upon
learning of pregnancy status. While this may reflect an inadequate knowledge of how to treat
pregnant women and may result in delayed receipt of appropriate therapy, referral is preferable
to giving an incorrect medication and allows for a complete assessment of the pregnant
woman. Creation of clear guidelines for referral to HFs and dissemination of the correct diag-
nostic and treatment regimens are needed to facilitate correct MiP case management in DOs;
only 8% of DOs were in possession of the 2010 MTGs.
Quinine, the recommended treatment in first-trimester pregnancies, was almost never
offered, and when it was, dosage was generally incorrect. Poor knowledge of the correct quinine
dosage compared to that of other commonly prescribed antimalarials, such as AL, was also
observed in the provider survey. At HFs, only 57% of women in first trimester were prescribed
quinine, and approximately 60% of those were given an insufficient supply or incorrect instruc-
tions. In contrast, only 25% of women given AL received an incorrect dose. These errors
resulted in quinine prescriptions ranging from 10–70% of the full dose, increasing the risk of
treatment failure and development of drug resistance [28–31].
Quinine was not offered to any of the simulated clients in DOs. This is not surprising given
that not a single DO provider cited quinine as the drug of choice for women in the first trimes-
ter of pregnancy, suggesting that knowledge, rather than quinine availability or pricing, was the
primary issue. However it is notable that quinine (median price = $2.31) was more expensive
than AL (median price $0.94) [23]. Inadequate prescribing practices are particularly concern-
ing because quinine is currently the only safe and effective treatment available to women in
early pregnancy.
SP was given preferentially to pregnant women in both HFs and DOs; almost 90% of SP pre-
scription in HFs was for treatment of pregnant clients. In many cases in DOs, providers
switched therapy from AL to SP after learning that a woman was pregnant. This practice high-
lights the significant knowledge gap; 49% of DO and 33% of HF providers incorrectly reported
that SP could be used for both treatment and prevention. These data raise serious concerns
about the dissemination and adoption of treatment guidelines in both the health-facility and
drug-outlet sectors, and is particularly alarming in light of the fact that SP has not been recom-
mended as a treatment in Kenya since 2004 [3,10]. Using SP as treatment is associated with a
high risk of treatment failure, which could have serious negative health consequences for both
the mother and fetus [32–34].
Although other studies have found that availability of drugs and diagnostics, cost, and
patient preference all influence provider adherence to case-management guidelines [11,13], in
this study, knowledge seemed to be the primary predictor of prescribing practice, particularly
in HFs. Most HF had diagnostic tests available [9], all facilities had quinine and AL in stock on
the day of the survey, and these drugs are given for free in HFs [23]. Furthermore, no HF
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provider cited patient preference as a reason for prescribing medicines during the knowledge
assessment interviews. In DOs, the situation was a bit different: diagnostic capacity was limited
[9], only 34% of DOs in the HDSS had quinine in stock at the time of the survey [23], quinine
was more expensive than AL (median prices $2.31 and $0.94, respectively) [23], and 8% of pro-
viders did cite drug availability and patient preference as a factor influencing drug choice. This
may reflect the differences in the clients seeking care from HF versus DOs- previous studies
have found that patients concerned about affordability, access, and acquiring their drug of pref-
erence are more likely to seek treatment from drug outlets [35].
Improving Provider Knowledge of and Adherence to the National Malaria
Treatment Guidelines
Health-facility providers had significantly greater knowledge of MiP consequences, clinical
symptoms, pregnancy assessment, and treatment regimens versus DO providers. However, the
only significant indicators for correct knowledge were malaria management training and pro-
fessional cadre, which was reflected in the differences by facility type, consistent with previous
findings [13]. Training alone has been shown to have limited impact on provider case manage-
ment practice [13]. Although this study was conducted in the HDSS area, the study did not
make use of the HDSS structures, and facilities with ongoing studies were excluded. Therefore,
these results are generalizable to the non-HDSS setting in Kenya, and likely to other countries
in sub-Saharan Africa.
A different combination of approaches and interventions are likely to work for HFs versus
DOs. Knowledge survey results showed that media plays an important role as source of infor-
mation for both HF and DO providers and should be explored as a potential platform for pro-
viding health messages. The use of mobile phone text-message reminders (mHealth) has been
shown to improve malaria case management practice for children in Kenya, and could be com-
bined with simple, focused training to improve case management in pregnancy [36]. Team-
based quality improvement has been suggested as another method to improve provider prac-
tice [37]. Whether DOs should strictly refer, or can also actively manage MIP cases, is likely to
require policy clarification, particularly with respect to each DO category. The role and place of
registered pharmacies in the health system and market can vary significantly from other DOs
that are not registered with an official regulatory body. Updated guidance for all entities must
be disseminated along with targeted MiP trainings and point-of-service job aids with increased
adherence to Ministry of Health supportive supervision guidelines [13,37,38]. New govern-
ment policy that regulates and provides clear guidelines for registered drug outlet practice is
needed in light of the dismal performance observed. Governmental recognition of informal
drug outlets, under the recommended regulation and guidance, may also be relevant given
patient health-seeking behaviours. A registration system for informal DOs, similar to that of
the accredited drug-dispensing outlets in Tanzania, may increase competition with registered
pharmacies and incentivize both entities to improve their practice through public recognition
of DO entities with higher knowledge levels [39].
Improvement of pregnancy assessment is needed but will be a challenge due to socio-cul-
tural factors that influence both a woman’s willingness to disclose pregnancy status and a pro-
vider’s willingness to ask. Adequate guidelines for pregnancy assessment of all WOCBA and
interactive trainings must be available so that providers feel comfortable inquiring about
potential pregnancy. Providers must clearly explain the purpose of the pregnancy assessment
(i.e., to ensure adequate and safe treatment) and be prepared to refer the patient for ANC ser-
vices [40]. In addition, a community outreach component to educate women on the impor-
tance of sharing pregnancy status with healthcare providers will likely be needed to facilitate
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the patient/ provider interaction. Multiple coordinated approaches and overall capacity build-
ing will be important keys to the improvement of MiP case management practice across facili-
ties and has been shown to be effective in the region [37,38].
Limitations & Challenges
The relatively short time-frame of the study limited the number of exit interviews. In particu-
lar, the identification of febrile patients in first trimester was challenging, probably due to limi-
tations in early pregnancy detection. Gestational age assessment was based on reported LMP,
which could have led to misclassification of pregnancy trimester for late first trimester preg-
nancies. However, unless the provider used an alternative approach to assess gestation (e.g.,
fundal height) it is unlikely that assessment of correct practice would have been affected.
Exit interviews and provider surveys were susceptible to courtesy or social-desirability bias,
meaning that respondents may have provided answers they thought were ‘more correct’ or that
the interviewer wanted to hear. Data obtained from exit interviews might be biased due to
patient recall or information loss, although the interview was conducted immediately upon
completion of the consultation to minimize this factor. In addition, errors may have been
introduced if the patient did not understand the information given or procedures completed
by the provider. Finally, in the health facility exit interviews, we did not record whether patients
had been seen in the ANC or the OPD, nor whether the woman had been seen in the ANC ear-
lier during the pregnancy. This limits our ability to assess whether pregnancy testing was
needed for a particular woman, as well as to identify where to target additional training.
Conclusion
We observed very poor case management practice and knowledge for malaria in pregnancy in
both HFs and DOs in Siaya County, western Kenya. Particularly concerning were the failure of
providers to assess WOCBA for pregnancy status, incorrect treatment with SP, inadequate qui-
nine dosage, and AL prescribed in first-trimester pregnancies. Multifaceted approaches, includ-
ing focused trainings, mHealth, team-based quality improvement, and supportive supervision
should be implemented to improve provider adherence and knowledge. These approaches
should be tailored specifically for HFs and DOs given the unique provider qualifications and
patient health-seeking behaviours that characterize the two entities. Improving practice in the
informal sector is critical, as it comprises a large part of health service provision for malaria
treatment and has little-to-no regulatory oversight. Optimizing treatment of WOCBA and
pregnant women is critical to prevent adverse consequences of MiP.
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